Transplantační medicína

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
^{Dehbi HM, et al. Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51.}